Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapi...
What are the potential upside and downside scenarios for the stock based on upcoming trial results and regulatory pathways?
Does the magnitude of relapse risk reduction outperform the current standard of care, and how might that influence pricing and reimbursement strategies?
What are the expectations for enrollment and data readout from the next‑generation trial cohorts, and how might those milestones move the share price?
24 days ago